AOD-9604 Dosage Guide: Protocols, Calculator & Safety

Beginner AOD-9604 Protocol — Honest Framing:

Critical Disclosure First: Before detailing any protocol, it is essential to state: AOD-9604 failed its pivotal Phase 2B obesity trial. Clinical trial evidence does not support that AOD-9604 produces meaningful weight loss in humans. The protocol below reflects what is commonly done in peptide optimization communities and is provided for informational completeness, not as a recommendation of efficacy.

Typical Starting Protocol:

Format: Subcutaneous injection, daily Dose: 250-300 mcg once daily Timing: Morning, fasted state (30+ minutes before food) Injection site: Abdominal fat (pinch-and-inject technique) Duration: 12-week trial minimum to assess individual response

Reconstitution and Dosing:

• Vial: typically 2 mg or 5 mg lyophilized powder
• Reconstitution: add 2 mL bacteriostatic water to 2 mg vial → concentration 1 mg/mL = 1000 mcg/mL
• For 250 mcg dose: draw 0.25 mL (25 units on insulin syringe marked 1 mL = 100 units)
• For 300 mcg dose: draw 0.30 mL (30 units)
• Use 27-30 gauge insulin syringe (U-100 scale)

Injection Technique:

• Swab site with alcohol, allow to dry
• Pinch subcutaneous fat (abdomen below umbilicus, or lateral thigh)
• Insert needle at 45-90° angle depending on needle length and subcutaneous thickness
• Inject slowly over 5-10 seconds
• Withdraw needle, apply light pressure with clean cotton/gauze
• Dispose of needle in sharps container

Rotation Schedule:

• Alternate abdomen / thigh daily to prevent lipoatrophy
• Within abdomen: different quadrants in rotation
• Avoid injecting directly into navel area

Storage:

• Lyophilized (unreconstituted): refrigerate, stable for 2+ years
• Reconstituted with bacteriostatic water: refrigerate, use within 3-4 weeks
• Protect from light
• Do not freeze reconstituted solution (affects peptide integrity)

Baseline and Monitoring: Before starting:

• Body weight and composition (DEXA scan if possible, or at minimum tape measurements and photos)
• Waist circumference at umbilicus
• Body fat percentage (bioelectrical impedance if no DEXA)
• Fasting metabolic panel if health relevant
• Baseline photos (consistent lighting, pose, time of day)

During protocol (every 2-4 weeks):

• Weight and circumferences at consistent conditions
• Progress photos
• Subjective assessment of energy, sleep, appetite, body composition
• Notes on concurrent nutrition and training compliance

What to Expect (Realistic):

• Weeks 1-4: no noticeable subjective effects typical; injection routine established
• Weeks 4-8: some users report mild subjective changes (appetite, energy)
• Weeks 8-12: meaningful objective changes unlikely from AOD-9604 alone; any changes observed likely reflect concurrent nutrition/training changes or placebo response
• Honest assessment at 12 weeks: compare before/after metrics; weight loss beyond what diet and exercise alone would achieve is probably not attributable to AOD-9604

When to Discontinue:

• No measurable objective change at 12 weeks: discontinue, consider evidence-based alternatives
• Injection site issues: discontinue
• Any unusual symptoms: discontinue, evaluate
• Achievement of goal through other interventions: discontinue as unnecessary

Supplementary Essentials (Actually Produce Fat Loss):

• Caloric deficit: 300-500 kcal below maintenance for sustainable fat loss
• Protein: 1.2-1.6 g/kg body weight daily to preserve lean mass
• Resistance training: 2-3x/week minimum
• Sleep: 7-9 hours nightly
• Manage stress (cortisol opposes fat loss)

These lifestyle factors are the evidence-based foundation; AOD-9604 (if used) is at most an uncertain adjunct.

Cost Consideration: Research peptide AOD-9604: typically $50-100 per month at 250 mcg daily dose. Over 12 weeks: $150-300. Compare to:

• GLP-1 agonists (clinically effective): $100-1000+/month depending on source
• Certified personal trainer for resistance training: variable
• Sleep tracker and sleep hygiene investment: one-time, high ROI
• Nutrition tracking app: free

Honest cost-benefit: the $150-300 for a 12-week AOD-9604 trial is likely better invested in a monthly nutritionist consult, quality gym membership, or sleep optimization, given AOD-9604's lack of efficacy evidence.

Intermediate AOD-9604 Protocol — Combination Strategies:

For users who have completed a beginner monotherapy trial and wish to continue exploring AOD-9604 in combination with other interventions, or who are starting directly with a stack approach.

Honest Disclaimer: AOD-9604 failed its pivotal obesity trial. Any combination protocol derives its real efficacy from the other components; AOD-9604's contribution is speculative. Combinations below are described for informational completeness with honest attribution of what's actually driving results.

Combination 1: GH Axis Optimization

Daily Protocol:

• AOD-9604: 300-500 mcg SC in morning fasted state
• Ipamorelin: 200-300 mcg SC before bed
• CJC-1295 (without DAC): 100 mcg SC before bed
• OR: Ipamorelin/CJC-1295 (no-DAC) combined 3x daily (200 mcg Ipamorelin + 100 mcg CJC-1295 per dose)

Real mechanism: Ipamorelin is a ghrelin mimetic/GHRP-6 analog that stimulates pulsatile GH release. CJC-1295 (no-DAC) is a short-acting GHRH analog. Together they produce synergistic GH pulses, potentially supporting body composition through IGF-1-mediated effects and direct GH signaling. AOD-9604 adds no independent proven contribution but also no significant additive cost or risk.

Expected outcomes (primarily from Ipamorelin/CJC-1295):

• Improved sleep quality within 2-4 weeks
• Modest fat loss over 12-16 weeks (1-2% body fat)
• Lean mass preservation during caloric deficit
• Improved recovery from training
• IGF-1 rise (monitor with lab testing at 8 weeks)

Monitoring:

• IGF-1: baseline, 8 weeks, 16 weeks (target 200-300 ng/mL)
• Fasting glucose: baseline, 8 weeks (GH can impair glucose tolerance at higher doses)
• DEXA body composition: baseline, 12-16 weeks

Combination 2: Comprehensive "Fat Loss" Stack

Daily Protocol:

• AOD-9604: 300 mcg SC morning fasted
• MOTS-c: 5 mg SC 2-3x weekly
• Tesamorelin: 2 mg SC daily (FDA-approved if prescribed; research peptide if sourced outside clinical channels)
• Adequate caloric deficit (300-500 kcal below maintenance)
• Resistance + cardiovascular training

Real mechanism: Tesamorelin has Phase 3 evidence for visceral fat reduction — it's the efficacy driver. MOTS-c has emerging evidence for mitochondrial metabolic effects (less robust data). AOD-9604 is the weakest link mechanistically.

Expected outcomes:

• Visceral fat reduction measurable on DEXA or abdominal MRI within 12-16 weeks
• Attribution: Tesamorelin primary, MOTS-c possibly secondary, AOD-9604 negligible
• Standard GH-axis monitoring for Tesamorelin

Combination 3: With GLP-1 Class (Real Weight Loss)

Daily Protocol:

• Semaglutide 2.4 mg weekly SC (or tirzepatide 5-15 mg weekly, or oral orforglipron if available)
• AOD-9604 250 mcg SC daily (optional adjunct)

Real mechanism: GLP-1 agonist is producing 90%+ of the weight loss effect. AOD-9604 contribution is marginal and unproven. Inclusion of AOD-9604 in this protocol is essentially ornamental.

Expected outcomes:

• Weight loss: 10-20% at 6-12 months (depending on GLP-1 agent and dose)
• AOD-9604 attribution: negligible
• Consideration: AOD-9604 is adding cost and injection burden without proven benefit; many practitioners would recommend dropping it

Combination 4: Recovery and Body Composition

Protocol:

• AOD-9604: 300 mcg SC morning
• BPC-157: 250 mcg SC twice daily for acute injury; intermittent for maintenance
• TB-500 (Thymosin Beta-4): 2 mg SC twice weekly for injury recovery

This stack is oriented toward injury recovery and tissue healing rather than pure fat loss. AOD-9604 is included peripheral to recovery goals.

Combination 5: The "Peptide Skeptic" Approach

Protocol:

• Drop AOD-9604 entirely
• Focus on Tesamorelin OR Ipamorelin/CJC-1295 for peptide-based body composition support
• Use GLP-1 agonist for weight loss if clinically indicated
• Emphasize evidence-based lifestyle interventions

For many sophisticated users, this simpler approach produces better outcomes than complex stacks that include AOD-9604.

Cycling Considerations:

• AOD-9604: no specific cycling concern; can be used continuously
• Ipamorelin/CJC-1295: some users cycle 8 weeks on, 4 weeks off; theoretical basis for HPA axis rest, though not well established
• Tesamorelin: continuous use per clinical protocols
• GLP-1 agonists: continuous use for weight loss goals

Monitoring Frequency (Intermediate Protocol):

• IGF-1: every 8-12 weeks
• Comprehensive metabolic panel: every 3-6 months
• HbA1c: every 6 months (if on GH secretagogues with possible glycemic effects)
• Body composition: every 12-16 weeks (DEXA ideal)
• Symptoms and subjective response: weekly self-assessment

Progressive Optimization: If results are disappointing at 16-20 weeks:

• Evaluate stack for redundancy and cost
• Consider dropping AOD-9604 and reallocating resources
• Intensify lifestyle interventions (strength training frequency, cardiovascular volume, nutrition precision)
• Consider evidence-based medications (GLP-1, Tesamorelin) if not already in protocol
• Accept that some genetic body composition targets may not be achievable through peptides alone

Advanced AOD-9604 Protocol - Expert-Level Considerations:

For highly experienced users, clinicians managing peptide-requesting patients, or those with specific complex scenarios.

Scenario 1: The "I Want to Try AOD-9604 Despite Weak Evidence" Patient

Common patient profile: educated consumer aware that the human obesity program did not confirm efficacy but wants to try AOD-9604 anyway based on anecdotal reports or mechanistic rationale.

Approach:

• Explicit informed consent regarding the lack of human efficacy evidence
• Define clear trial endpoint: 12 weeks at 500 mcg daily as an adequate test of individual response
• Objective baseline metrics: DEXA body composition, photos, comprehensive labs
• Concurrent optimization: nutrition, training, sleep all controlled/documented
• Honest assessment at 12 weeks: compare observed changes to what would be expected from lifestyle interventions alone
• Pre-specified discontinuation criteria if no measurable benefit
• This approach respects patient autonomy while ensuring they're not wasting resources indefinitely

Scenario 2: Research Peptide Quality Control

Given AOD-9604 is exclusively sourced outside pharmaceutical supply chains for injection, quality varies dramatically.

Quality-focused approach:

• Source from vendors providing a third-party certificate of analysis (COA)
• Verify COA includes: peptide identity (mass spectrometry), purity (HPLC >95%), endotoxin testing (<1 EU/mg), sterility for sterile-filtered product
• Reject vendors unwilling or unable to provide a recent COA for the specific lot
• Visual inspection on receipt: intact seal, clear vial with no visible particulates, proper labeling
• Reconstitute under clean technique; discard if cloudy or with visible contaminants
• When switching suppliers, repeat baseline assessment

Scenario 3: Combination With Advanced Body Recomposition Protocols

For bodybuilders or elite athletes pursuing optimized body composition (note: AOD-9604 is prohibited by WADA - see contraindications):

Comprehensive Stack (example):

• AOD-9604 500 mcg SC daily (fasted morning)
• Tesamorelin 2 mg SC daily (evening)
• Ipamorelin 300 mcg + CJC-1295 no-DAC 100 mcg SC 3x daily (pulsatile GH)
• MOTS-c 5 mg SC 2x weekly
• Testosterone optimization (TRT if hypogonadal, or enclomiphene for endogenous support)
• HCG 500 IU SC 2x weekly for testicular function preservation (if on TRT)
• Creatine monohydrate 5 g oral daily
• Protein 2.0-2.2 g/kg lean body mass
• Structured 4-5 day strength training
• Cardiovascular conditioning 150+ min/week moderate + 2x weekly HIIT
• Sleep tracking with 8+ hour target
• Caloric cycling: maintenance on training days, 500 kcal deficit on rest days

Cost: significant ($500-1500+/month depending on peptide sourcing) Efficacy attribution:

• Primary drivers: training, nutrition, testosterone optimization
• Secondary: Tesamorelin (for visceral fat), Ipamorelin/CJC-1295 (for GH pulses)
• AOD-9604: unclear, possibly ornamental

Monitoring:

• DEXA: every 12 weeks
• Testosterone, free T, estradiol: every 3 months
• IGF-1: every 8 weeks
• Comprehensive metabolic panel: quarterly
• Lipid panel: every 6 months

Scenario 4: Post-Bariatric / Significant Weight Loss Patients

Patients after substantial weight loss (bariatric surgery or GLP-1-mediated) often have residual body composition concerns (loose skin, visceral fat remnants, lean mass preservation needs).

Protocol:

• Continue primary weight loss intervention as indicated
• Add Tesamorelin for residual visceral fat (evidence-based)
• Add Ipamorelin/CJC-1295 for GH support
• Optional: AOD-9604 500 mcg daily (poor evidence but low risk)
• Aggressive protein (2.0+ g/kg lean body mass)
• Resistance training as non-negotiable
• Realistic skin surgery discussion if skin redundancy is functionally problematic

Scenario 5: Transitioning Patients Off AOD-9604

Patients who have been using AOD-9604 for extended periods and want to discontinue or optimize:

Approach:

• No taper required (no withdrawal syndrome; no receptor downregulation concerns)
• Simply discontinue and redirect resources
• Assess what concurrent interventions were providing value
• Consider cycling to evidence-based alternatives
• No physiological concerns; primary question is psychological transition away from a familiar protocol

Scenario 6: Clinical Practice Considerations

For practitioners (MDs, NPs, PAs) asked about AOD-9604 by patients:

Patient education talking points:

• Acknowledge patient interest and research
• Share that AOD-9604's human obesity program did not confirm efficacy and was discontinued, and that there is no published, peer-reviewed human trial demonstrating weight-loss benefit (be aware that widely circulated citations of a '2008 Heffernan' obesity trial are erroneous - the real Heffernan AOD9604 papers are 2001 rodent studies)
• Explain the GRAS determination is a food-safety determination, not efficacy
• Note it is prohibited in sport by WADA
• Discuss evidence-based alternatives: GLP-1 agonists, Tesamorelin, lifestyle
• Respect patient autonomy if they choose to proceed
• Document shared decision-making

Risk management:

• AOD-9604 is not FDA-approved for any indication
• Prescribing or recommending it as therapy may expose to professional liability depending on context
• Supplement form (oral, low-dose) is legally distinct from compounded or research injectable form
• Document informed consent thoroughly

Scenario 7: The Gray Market Peptide Ethics

For patients asking practitioners about research peptide AOD-9604:

• Most practitioners cannot prescribe or directly supply research peptides (they're not pharmaceutical products)
• Compounding pharmacies may legally compound AOD-9604 with a prescription (limited availability)
• Patients sourcing independently online: the practitioner role is harm reduction (injection technique, quality assessment, recognizing adverse events) rather than endorsement
• Document discussions clearly

Long-Term Considerations:

• AOD-9604 has been used by individuals for years at various doses without clear safety signals in the peptide community
• Absence of evidence is not evidence of absence for long-term risks
• Periodic reassessment of cost-benefit: is continuing use producing demonstrable benefit, or just routine?
• As the weight loss pharmacology landscape evolves (GLP-1, GIP, glucagon, amylin combinations), AOD-9604's relative position becomes weaker over time

Key Advanced Insight: The most sophisticated peptide users tend to include AOD-9604 briefly and then move away from it as experience demonstrates other peptides produce more measurable results. If you find yourself in an "AOD-9604 is my core peptide" mindset after 6+ months of use, consider whether you have been pursuing the most impactful interventions.

The peptide and obesity pharmacology landscapes have changed dramatically since AOD-9604 was developed in the 1990s. Contemporary options - Semaglutide, Tirzepatide, Orforglipron, Mazdutide, Retatrutide, Tesamorelin, Cagrilintide - provide superior evidence, efficacy, and clinical support for fat loss and body composition goals.